External therapy of Chinese herbal medicine in the treatment of severe rash of aletinib accompanied by hepatic insufficiency:a case report

YU Yi-xuan; ZHENG Yu-min; CUI Hui-juan

doi:10.16025/j.1674-1307.2022.09.031

您当前的位置：

首页 >

文章列表页 >

External therapy of Chinese herbal medicine in the treatment of severe rash of aletinib accompanied by hepatic insufficiency:a case report

更新时间：2023-06-16

- External therapy of Chinese herbal medicine in the treatment of severe rash of aletinib accompanied by hepatic insufficiency:a case report
- Beijing Journal of Traditional Chinese Medicine Vol. 41, Issue 9, Pages: 1069-1071(2022)
- 作者机构：
  
  1.北京中医药大学研究生院，北京 100029
  2.中日友好医院中西医结合肿瘤内科，北京 100029
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2022.09.031
  CLC：
扫描看全文
俞仪萱，郑玉敏，崔慧娟.中药外用治疗阿来替尼重度丘疹样皮疹伴肝功能不全1例［J］.北京中医药，2022，41（9）：1069-1071.

YU Yi-xuan,ZHENG Yu-min,CUI Hui-juan.External therapy of Chinese herbal medicine in the treatment of severe rash of aletinib accompanied by hepatic insufficiency:a case report[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(09):1069-1071.
俞仪萱，郑玉敏，崔慧娟.中药外用治疗阿来替尼重度丘疹样皮疹伴肝功能不全1例［J］.北京中医药，2022，41（9）：1069-1071. DOI： 10.16025/j.1674-1307.2022.09.031.

YU Yi-xuan,ZHENG Yu-min,CUI Hui-juan.External therapy of Chinese herbal medicine in the treatment of severe rash of aletinib accompanied by hepatic insufficiency:a case report[J]. Beijing Journal of Traditional Chinese Medicine,2022,41(09):1069-1071. DOI： 10.16025/j.1674-1307.2022.09.031.

摘要

Abstract

关键词

非小细胞肺癌阿来替尼皮疹中药外治病例报告

Keywords

references

赫捷,李霓,陈万青,等.中国肺癌筛查与早诊早治指南（2021，北京）[J].中国肿瘤,2021,30(2):81-111.

SOLOMON B,VARELLA-GARCIA M,CAMIDGE DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer[J].J Thorac Oncol,2009,4(12):1450-1454.

MIDHA A,DEARDEN S,MCCORMACK R.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)[J].Am J Cancer Res，2015,5(9):2892-2911.

ZHOU C,KIM SW,REUNGWETWATTANA T,et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA):a randomised phase 3 study[J].Lancet Respir Med,2019,7(5):437-446.

FREITES-MARTINEZ A,SANTANA N,ARIAS-SANTIAGO S,et al. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J].Actas Dermosifiliogr (Engl Ed),2021,112(1):90-92.

SINGH A,CHEN H.Optimal care for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer: a review on the role and utility of ALK inhibitors[J].Cancer Manag Res,2020,1(12):6615-6628.

MOK T,CAMIDGE DR,GADGEEL SM,et al.Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J].Ann Oncol,2020,31(8):1056-1064.

SETO T,KIURA K,NISHIO M,et al.CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study[J].Lancet Oncol,2013,14(7):590-598.

PETERS S,CAMIDGE DR,SHAW AT,et al.Alectinib versus Crizotinib in untreated ALK-Positive non-small-cell lung cancer[J].N Engl J Med,2017,377(9):829-838.

HIDA T,NOKIHARA H,KONDO M,et al.Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial[J].Lancet,2017,390(10089):29-39.

SHIRASAWA M,KUBOTAA M,HARADA S,et al. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma:A case report[J].Lung Cancer,2016,99(9):66-68.

KIMURA T,SOWA-OSAKO J,NAKAI T,et al.Alectinib-induced erythema multiforme and successful rechallenge with alectinib in a patient with anaplastic lymphoma kinase-rearrangedlung cancer[J].Case Rep Oncol,2016,9(3):826-832.

ANDERSON BE,LUCZAK TS,RIES LM,et al.Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash[J].J Oncol Pharm Pract,2020,26(8):2028-2030.

王可，李娟，孙建国.间变性淋巴瘤激酶抑制剂不良反应管理西南专家建议（2021年版）[J]. 中国肺癌杂志, 2021，24(12):815-828.

彭孟凡,田硕,刘保松,等.中西药外治机制和特点分析[J].中医学报,2018,33(12):2323-2328.

项丽玲,苗明三,曹利华,等.“有毒”中药外用安全性思考[J].中国中药杂志,2019,44(8):1710-1714.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of Qilian Fuzheng Capsule for intervention of compound inflammatory markers in patients with non-small cell lung cancer

Analysis of traditional Chinese medicine in treating tumor targeted and chemotherapy-related rash

Related Author

No data

Related Institution

中国中医科学院研究生院

山东中医药大学

北京中医药大学东直门医院呼吸科

北京中医药大学

北京大学人民医院中医科

⁰